期刊文献+

北京地区CYP450药物代谢基因多态性抽样统计研究 被引量:1

Statistical study on the polymorphorisms of Cytochrome P450 genes in Beijing residents
原文传递
导出
摘要 目的调查北京地区的药物代谢酶系CYP450相关的基因型分布情况,为北京地区的个性化用药指导提供建议。方法本文涉及的研究通过在北京地区抽样使用Taqman方法进行了CYP450相关的基因型检测,估算出了在北京地区5个CYP基因中的6个SNP位点的基因型的分布情况。结果其中,CYP2C19-b和CYP3A4两个基因中所检测的位点所对应的比重最小的基因型在北京市人口中的比重接近于0。本研究说明,CYP2D6和CYP2C19两个基因的基因型在北京市人口中呈现较高的多态性分布,医师在使用涉及到这两个基因参与代谢的药物时,可以参考CYP450基因型检测结果。结论建立针对我国不同地区的CYP450基因型数据库对于医疗卫生体系有重要作用。 Objective To investigate the genotype distribution of Cytochrome P450(CYP450) genes in Beijing residents and facilitate personalized medication.Methods 400 Beijing residents were randomly sampled and tested for the 6 single nucleotide polymorphorisms(SNPs)of 5 CYP genes with Tapman method.We calculated the proportions of genotype distribution for the tested SNP sites of CYP450 in Beijing residents statistically.Results CYP2D6 and CYP2C19 are the major genotypes of CYP450 genes in the residents of Beijing.The proportions of CYP2D6 and CYP2C19 genotypes are significantly higher than the proportion of any other genotype of CYP genes at SNPs(P〈0.05).The genotype distributions of CYP2C19-b and CYP3A4 are close to non-existent.Additional attention should be given to drugs with certain genotype of CYP450 mediated metabolism.Conclusion It would be very helpful for clinical drug prescription to establish the SNPs genotype distribution database of CYP 50 genes.
出处 《中国预防医学杂志》 CAS 2011年第2期155-157,共3页 Chinese Preventive Medicine
关键词 个性化用药 药物相互作用 CYP450 基因型 单碱基多态性(SNP) Taqman方法 Personalized medication Drug interaction CYP450 Genotype Single nucleotide polymorphorisms(SNPs) Taqman method
  • 相关文献

参考文献10

  • 1Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects [J].Am Fam Physician, 2007, 76 (3): 391-396.
  • 2Wilkinson GR. Drug metabolism and variability among patients in drug response [J]. N Engl J Med, 2005, 352 (21): 2211- 2221.
  • 3Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomies in reducingadverse drug reactions: a sys- tematic review [J].JAMA, 2001, 286 (18): 2270-2279.
  • 4Special report: genotyping for cytochrome P450 polymorphisms to determinedrug metabolizer status [R].Technol Eval Cent Asses Program Exec Summ, 2004, 19 (9): 1-2.
  • 5Dresser GK, Spence JD, Bailey DG. Pharmacokineticpharmaco dynamic consequences and clinical relevance of cytochronm P450 3A4 inhibition [J].Clin Pharmacokinet, 2000, 38 (1): 41-57.
  • 6周艳钢,李焕德.体内药物代谢研究的意义与应用[J].中南药学,2009,7(1):46-50. 被引量:14
  • 7Guengerich FP. Cytochrome p450 and chemical toxicology [J]. Chem Res Toxicol, 2008, 21 (1): 70 - 83.
  • 8Chul Ahn. Pharmacogenomics in drug discovery and develop- ment[J].Genomics Informat, 2007, 5 (2): 41-45.
  • 9Womaek C, As part of retrofitting, FDA panel votes to relabel warfarin for PGx: Is Dx far behind?[R].Pharmaeogenomics Reporter, 2005, November 24. http: //www. genomeweb. com/dxpgx/part-retrofitting-fda-panel votes-relabel-warfarin- pgx-dx-far-behind.
  • 10周健,吕虹,康熙雄.药物代谢酶CYP2D6和CYP2C19的基因多态性与个体化治疗[J].中国医药生物技术,2009,4(4):299-302. 被引量:18

二级参考文献18

共引文献30

同被引文献31

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部